Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
05 janv. 2023 08h00 HE
|
Reset Pharmaceuticals Inc.
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental...
Ketamine Media Scheduled to Launch North America's Largest Psilocybin Awareness Network
21 déc. 2022 10h30 HE
|
Ketamine Media
KNOXVILLE, Tenn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Ketamine Media announced today that it is in the final stages of launching its digital ecosystem of premium online properties to raise awareness...
Galexxy Holdings Inc., Announces its Intention to Pursue Dual Listing on the Upstream Platform
16 nov. 2022 09h00 HE
|
Galexxy Holdings Inc.
Newport Beach, CALIFORNIA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Galexxy Holdings Inc., (“Galexxy” or “Company”) (OTC: GXXY) announced today that following a recent board meeting, the directors of the...
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
16 nov. 2022 07h30 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors
02 nov. 2022 08h00 HE
|
Reset Pharmaceuticals Inc.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development and commercialization of novel...
Optimi Health Announces Closing of Strategic Non-Brokered Private Placement
11 oct. 2022 09h00 HE
|
Optimi Health Corp.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. Highlights: ...
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
06 oct. 2022 12h51 HE
|
Optimi Health Corp.
Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable...
Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
22 sept. 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...
MindSite News Launches Live Conversation Series on Psychedelics and Mental Health
20 sept. 2022 11h00 HE
|
MindSite News
OAKLAND, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MindSite News—the only news site dedicated exclusively to reporting on mental health in America—is launching a live public conversation series...
Galexxy Holdings Announces a $1,000,000 Non-Dilutive Revolving Credit Facility
20 sept. 2022 09h00 HE
|
Galexxy Holdings Inc.
Newport Beach, CALIFORNIA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Galexxy Holdings Inc., (“Galexxy” or “Company”) (OTC: GXXY) is pleased to announce it has arranged a $1,000,000 non-dilutive revolving...